Archive · 20 Sep 2025
New Alzheimer's Drugs and Early Diagnosis Show Progress
Scientists are working hard to help people with Alzheimer's disease.
Two new drugs have been found that can slow down the disease, but they don't work very well and can have bad side effects.
A new blood test can now detect early signs of the disease, unlike the old, more invasive tests.
Experts are also looking into ways to prevent Alzheimer's by encouraging healthy habits like exercise and eating well.
Some countries have approved the new drugs and tests, while others are still deciding if they're worth the cost and risks.
Two new drugs, donanemab and lecanemab, are the first to significantly slow Alzheimer's progression.
The new drugs are modestly effective and can have serious side effects, including brain hemorrhages.
A new blood test has been developed to detect Alzheimer's biomarkers, replacing the invasive lumbar puncture.
The US has authorized the blood test, while Europe has not approved any yet.
Risk factors like obesity, smoking, and inactivity are linked to increased risk.
- Who
- Alzheimer's patients and researchers
- What
- Recent advances in Alzheimer's prevention, diagnosis, and treatment
- When
- Ahead of Alzheimer's Day
- Where
- Worldwide
- Why
- To provide hope and address the debilitating disease
Proponents
Skeptics
Drug Effectiveness
Proponents
The drugs, though costly, provide significant benefits.
Skeptics
The benefits do not outweigh the risks.
Early Diagnosis
Proponents
Blood tests alone are sufficient for diagnosis.
Skeptics
Clinical exams are still needed to confirm diagnosis.
- Primary Disease
- Alzheimer's Disease
- Drug Names
- Donanemab, Lecanemab (Leqembi)
- Drug Efficacy
- Modestly effective, slows progression
- Diagnosis Method
- Blood test (new), Lumbar puncture (old)
- Risk Factors
- Obesity, smoking, alcohol, inactivity, hearing loss